Anti-Factor VIII (FVI) antibodies were prepared by a combination of salt precipitation, gel filtration chromatography, and specific adsorption over insolubilized FYVM from the serum of 10 healthy subjects with normal levels of FVM. 
Introduction
Type A hemophilia is an inborn disease of the coagulation pathway and is characterized by a deficiency or dysfunction of 1 . Abbreviations used in this paper: BBS, borate-buffered saline; FVIII, Factor VIII; FT, flow-through; GBS, glycine-buffered saline; Lx, latex particles; OPD, ortho-phenylenediamine; r, recombinant; RT, room temperature.
cal manifestations of the disease include bleeding in the muscles, joints, and soft tissues and are optimally treated by infusions of FVIII. However, such treatment is complicated by the development of antibodies (usually described as "inhibitors") toward FVIII in a variable but significant proportion of the cases (3.6-50%; references 2-4). The development of inhibitors is particularly prevalent in patients with FVIII levels < 5% of normal values (4, 5) .
The occurrence of such anti-FVIII antibodies is a severe complication, which can practically preclude efficient FVIII replacement therapy. Therefore, much effort has been devoted both to improving our understanding of the reasons for the formation of anti-FVIII antibodies and to find alternative methods of treatment. Despite this effort, the mechanisms of production of anti-FVI antibodies are still largely unknown and treatment is limited nowadays to nonspecific measures such as cytostatic agents, infusions of pooled gammaglobulins (6) , or infusions of large amounts of FVIII in an attempt to induce tolerance (7, 8) .
We recently characterized the anti-FVIII antibody response of hemophiliac patients, a study which included the purification of antibodies by immunoaffinity (9) . In the process of validating the immunoadsorption procedure, we included a series of serum samples obtained from healthy subjects with normal levels of FVIII. Unexpectedly, a fraction of antibodies were specifically retained on the FVm immunosorbent; these could be recovered by elution with dissociating buffers.
Here we present evidence showing that these antibodies are bona fide anti-FVII antibodies and that their activity cannot be detected before their purification from serum. In addition, the immunoglobulin fraction that is not retained on the column inhibits the binding of anti-FVIH antibodies to FVM through recognition of their idiotypes.
Methods

Reagents and buffers
Human recombinant FVII (rFVIII) was obtained from Hyland (Glendale, CA) as material for laboratory use only; this preparation contained von Willebrand factor (vWf) but no stabilizer or other protein. Nhydroxysuccinimidyl-LC biotin was purchased from Pierce (Rockford, IL), human serum albumin (HSA) was from Institut Merieux (Lyon, France) , and PMSF was from Sigma Chemical Co. (St. Louis, MO). Buffers used were: phosphate-buffered saline, 8 mM, pH 7.4 (PBS); PBS containing 0.5% bovine serum albumin (PBS-BSA); PBS containing 0.1% Tween 20 (PBS-Tween) (Technicon, Tarrytown, NY); glycine-buffered saline, 270 mM, pH 9.2 (GBS); GBS containing 0.5% BSA (GBS-BSA); borate-buffered saline made of 20 mM boric acid in 150 mM NaCl, adjusted to pH 8.1 with NaOH (BBS); Tris, 10 Blood sample collection 10 healthy individuals (6 males and 4 females) volunteered to participate in the study. FVIII levels were assayed on citrated plasma and ranged from 64 to 128% of the normal value. Blood was taken by venipuncture and allowed to clot for 2 h at room temperature (RT). Serum was obtained by centrifugation at 3,000 g for 15 min and stored at -20OC until use.
Protein biotinylation rFVIII was dialyzed against a solution containing 150 mM NaCl and 10 mM CaCI2 (wash buffer) and diluted to 360 pg/ml in the same buffer. 100 pl of a 10 mg/ml stock solution of N-hydroxysuccinimidyl-LC-biotin in 150 mM NaCl was added to 1 ml of rFVIII; the mixture was incubated for 2 h at 40C and then dialyzed against the wash buffer. Human IgG, or F(ab' )2 fragments thereof, were labeled with biotin by the same method except for the use of 500 pg/ml protein and of a 150 mM NaCl solution without CaCl2.
Preparation of mouse monoclonal antibodies (mAbs) to FVIII 6-wk-old Balb/c mice were immunized with a preparation of human rFVIII suspended in CFA as described previously (9) . Hybridomas secreting anti-FVIII antibodies were identified by direct binding to polystyrene plates coated with 2 pg/ml rFVIII in 50 mM glycine buffer, pH 9.2. The binding of mouse IgG in the supernatants was detected by the addition of biotin-labeled goat IgG specific for mouse Fcy (Tago, Inc., Burlingame, CA). Positive hybridomas were cloned by limiting dilution and expanded. Antibodies were prepared from the supernatants by salt precipitation and gel filtration chromatography on AcA44 (Pharmacia AB, Uppsala, Sweden).
mAb characterization
IgG and IgG subclasses. The concentration and isotype of mAbs were evaluated by ELISA. Polystyrene microtitration plates (Nunc, Roskilde, Denmark) were coated with 50 pl of an anti-mouse Fcy goat IgG (Tago, Inc.) diluted to 5 pg/ml in PBS and incubated for 2 h at RT.
The plates were then washed four times with PBS-Tween before addition of 50 pl Tris-casein for 30 min at RT. After a second wash, a 50-pl aliquot of mAb was added, and the plate was incubated for 2 h at RT. The binding of mAbs was quantitated by addition of 50 p1 of peroxidaseconjugated goat IgG specific for mouse Fcy (Sigma Chemical Co.) diluted 1:4,000 in PBS-BSA, followed by 50 pl of ortho-phenylenediamine (OPD; Sigma Chemical Co.) diluted to 800 mg/liter in citratedphosphate buffer, pH 5. Absorbance was read at 492 nm in a Kontron SLT-210 spectrophotometer (SLT Lab instruments, Vienna, Austria).
For the determination of IgG subclasses, polystyrene microtitration plates (Nunc) were coated with 50 pl affinity-purified human FVIII (Hemofil M; Hyland) diluted to 2 pg/ml in PBS-BSA. After 2 h at RT, the plates were saturated with 50 pI Tris-casein and washed as above. 50 p1 of the supernatant containing an mAb was added for a 2-h incubation, and the plates were washed again. 50 Ml of a goat anti-mouse Fcy biotin-labeled IgG specific to either the IgG1, IgG2a, IgG2b, or IgG3 subclass (all from Amersham, Buckinghamshire, United Kingdom) was added at a 1:5,000, 1:1,000, 1:1,000, 1:2,000 dilution in Triscasein, respectively. After a further wash with PBS-Tween, 50 IL of PBS-BSA containing 1 pg/ml avidin-peroxidase was added for 30 min at RT. The plates were washed again, 50 Ml of OPD was added, and the reaction was read at 492 nm.
Immunoblotting. rFVIII was digested with thrombin and blotted onto nitrocellulose membranes after SDS-PAGE as described previously (9) .
Briefly, 2 pg of native or thrombin-digested rFVIII was separated on a 4-15% gel, and proteins were transferred on a 0.2-pm porosity nitrocellulose membrane (Machery-Nagel, Duren, Germany); the latter was cut in strips, which were blocked with 3% gelatine for 30 min and washed with PBS-Tween. Nitrocellulose strips were then incubated sequentially with 3 Mg/ml of a given mAb, a biotin-labeled goat IgG specific for mouse Fcy, avidin-peroxidase, and chloronaphtol. The strips were finally rinsed with distilled water.
FVIII inhibitory activity. The capacity of mAbs to neutralize the function of FVIII was evaluated in a clotting assay using the Bethesda method (10) and in a chromogenic assay in which thrombin-activated FVIII acts as a cofactor to Factor IXa in the conversion of Factor X to Factor Xa, that is measured through its enzymatic action over a colored substrate (Merz & Dade A.G., Dudingen, Switzerland) (11) . Briefly, 35 pi of a solution of 150 mM NaCl containing 10 mM CaCI2 and 100 ug/ml of the mAb to be tested was mixed for 30 min at 370C with 35 pi rFVIII at a dilution of 150 ng/ml in the same buffer. 50 p1 of the sample was then retrieved and mixed with the chromogenic assay reagents, namely, thrombin, phospholipids, FIXa, FX, and substrate, as recommended by the manufacturer. After an incubation of 10 min at RT, the absorbance was read at 405 nm. Control experiments included rFVIII diluted in buffer without antibodies.
FVIII immunosorbent
rFVIII was insolubilized by its carbohydrate moieties on a hydrazideactivated solid phase (Affigel-Hz; Bio-Rad Laboratories, Richmond, CA) as described previously (9) , with minor modifications. Briefly, human rFVIII was dialyzed against the coupling buffer supplemented with 10 mM CaCl2. HSA and PMSF were added so that the final preparation contained 100 pg rFVIII, 5 mg HSA, and 20 mM PMSF per ml. This preparation was oxidized by addition of 100 mM NaIO4 for 1 h at RT, followed by 20 mM glycerol for a further 10 min. Oxidized rFVIII was then dialyzed overnight at 40C against the coupling buffer containing 10 mM CaCl2 and then mixed with a suspension of Affigel-HZ at a ratio of 1.5 ml per milliliter of packed gel. An immunosorbent was prepared with HSA alone following exactly the same procedure.
Preparation of human anti-FVIII antibodies from normal subjects
Human anti-FVIII antibodies were prepared from serum by salt precipitation, gel filtration chromatography, and adsorption on insolubilized FVIII (9) . A 10-ml serum sample was obtained from each patient. Salt precipitation was carried out at 21°C by dropwise addition of phosphate buffer, 200 mM, pH 8.2, containing 360 g/liter Na2SO4. The precipitates were recovered by centrifugation at 8,000 g for 20 min after an overnight incubation at RT. The pellets were resuspended in PBS containing 1 M NaCl, and the samples were applied to a 90 X 5-cm TSK-HW55 Fractogel (Merck, Darmstadt, Germany) column equilibrated in the same buffer. IgG-containing fractions were pooled, concentrated to 20 ml by ultrafiltration on a YM1O membrane (Amicon, Danvers, MA), and dialyzed against PBS. A 5-ml aliquot of IgG was passed over a 6-ml column of FVIII-Affigel at a flow rate of 10 ml/h. The gel was then washed successively with 100 ml of wash buffer, 20 ml of 400 mM NaCl containing 40 mM CaCl2 and 25 mM imidazole, and finally 100 ml of wash buffer. Anti-FVIII antibodies were recovered by sequential elution with acid and alkaline buffers. 20 ml of acid buffer (50 mM imidazole, pH 4.5, containing 60% ethyleneglycol, 0.5% HSA, and 40 mM CaCl2) was passed through the column, followed by 100 ml of wash buffer and 20 ml of alkaline buffer (50 mM diethylamine, pH 10, containing 60% ethyleneglycol and 40 mM CaCl2). A final wash was carried out with 100 ml of wash buffer. The fractions eluted from the immunosorbent were adjusted to pH 7 and pooled. Both the immunoglobulin fraction recovered by column elution and containing anti-FVIII antibodies and the flow-through (FT) fraction, possibly containing antiidiotypic antibodies, were dialyzed against the coupling buffer containing 10 mM CaCl2 and stored at -20°C until use. Calcium was added to all antibody preparations for use in assays with soluble FVIII.
Control experiments included the immunoadsorption of purified IgG over an HSA immunosorbent column. Serum samples of 4 of the 10 blood subjects and 4 hemophiliac patients, of whom 2 had high levels of FVIII inhibitors (900 and 170 Bethesda units, respectively), were prepared and passed over the immunoadsorption column exactly as described above.
In some experiments, FT antibodies were digested by pepsin to generate F(ab' )2 fragments. This was carried out as follows: FT was dialyzed against 25 mM sodium acetate buffer, pH 4.5, and adjusted to 1 mg/ml. 1 ml of Pepsin Avidgel (Bioprobe International, Inc., Tustin, CA) was added to 2 ml of the immunoglobulin solution. The suspension was incubated for 5 h at 210C with continuous agitation and then centrifuged for 3 min at 5,000 g. The supernatant was brought back to neutral pH by addition of 3 M Tris. Undigested IgGi, 2, 4, and Fc fragments were eliminated from the solution by passage over protein A-Sepharose (HiTrap protein A; Pharmacia AB). No attempt was made to remove undigested IgG3 antibodies, which are not retained on protein A.
Evaluation of human IgG and IgG subclasses
The amount of IgG antibodies recovered by affinity purification and their isotype distribution were measured by ELISA as described previously (9) . Briefly, polystyrene microtitration plates (Nunc) were coated with anti-human Fcy goat IgG (Tago, Inc.) for 2 h at RT. The plates were washed, and a 50-IA aliquot of the sample was added for a further 2 h. The binding of IgG antibodies was quantitated by addition of peroxidase-conjugated goat IgG specific for human Fcy (Sigma Chemical Co.) and 50 [l OPD, and the plate was read at 492 nm. IgG subclasses were determined on plates coated with an anti-mouse IgGI rat monoclonal IgG (UCL, Brussels, Belgium), followed by a mouse IgG1 specific to either human IgGI (Oxoid Ltd., Basingstoke, United Kingdom), IgG2, or IgG3 (both from Calbiochem-Novabiochem, La Jolla, CA). For the determination of IgG4, the corresponding mouse antibody (Calbiochem-Novabiochem) was insolubilized directly on the plate. The sample or a dilution of a standard reference sample (Janssen, Beerse, Belgium) was added, and bound IgG were detected by addition of a horseradish peroxidase-conjugated goat IgG specific for human Fcy (Sigma Chemical Co.) and OPD.
Qualitative evaluation of antibodies recovered by immunoadsorption Affinity-purified antibodies. To evaluate whether the anti-FVIII activity detected in affinity-purified preparations was due to the presence of specific antibodies, the eluates were passed over a column of protein ASepharose (Pharmacia AB). Thus, 500-p1 samples of affinity-purified antibodies containing 60 ,ug/ml of IgG in 20 mM sodium phosphate buffer, pH 7.0, were loaded on 1-ml protein A-Sepharose columns. The latter was washed with 8 ml of the same buffer, and the FT fraction was concentrated down to 500 1l using an Amicon microconcentrator 10 (Amicon). The content of IgG was determined by ELISA as described above (see evaluation of human IgG). Dilutions of IgG-depleted samples were used in the FVIII assay systems described below.
The presence of antibodies towards vWf was evaluated using a direct binding ELISA. Polystyrene microtitration plates (Nunc) were incubated overnight at RT with a preparation of highly purified human vWf (kindly provided by Dr. Jef Arnout, Katholieke Universiteit, Leuven, Belgium) that had been diluted to 2 ,ug/ml in GBS. The binding of vWf to the plate was verified by addition of a specific mouse mAb (gift of Dr. Arnout). The plates were washed four times with PBSTween, and a 50-,l aliquot of affinity-purified antibodies made at 10 ,ug/ml in PBS was added for 2 h at RT. The plates were then washed as above, and bound IgG were quantitated by addition of 50 ,ul of peroxidase-conjugated goat IgG specific for human Fcy (Sigma Chemical Co.) diluted in PBS-BSA. 2 h later, the plates were washed as above, before addition of 50 Ml OPD and reading at 492 nm.
The proportion of anti-FVIII antibodies in the total yield of affinitypurified antibodies was evaluated by measuring their capacity to bind to soluble FVIII. Thus, antibodies were mixed with a preparation of FVIII (Hemofil M) containing vWf and were passed over a column on which anti-vWf antibodies had been insolubilized (9) . The proportion of antibodies retained on the column was taken as a measure of relative purity. Rabbit IgG antibodies to human vWf (DAKOPATTS, Copenhagen, Denmark) were oxidized with NaIO4 and coupled to Affigel-HZ essentially as described above for rFVIII. 10 mg of rabbit antibodies was used per milliliter of packed gel. Affinity-purified IgG antibodies of each of the 10 preparations were mixed with Hemofil M at a ratio of 1:50 (wt/wt) FVIII to antibody for I h at RT. 1 ml of the mixture, containing 2 pg antibodies and 40 ng FVIII, was passed over a 6-ml column of anti-vWf immunosorbent. The column was washed with PBSCaCl2, and bound complexes were eluted by passage of 25 ml acid buffer (50 mM imidazole, pH 4.5, containing 60% ethyleneglycol, 0.5% HSA, and 40 mM CaCl2). The eluate and FT fractions of the anti-vWf immunosorbent were dialyzed against 150 mM NaCl containing 10 mM CaCl2 and concentrated by ultrafiltration on a YMlO membrane (Amicon). The IgG content in both fractions was evaluated by ELISA. Control experiments included the substitution of anti-FVIII antibodies by the corresponding FT fraction.
FT fractions. FT fractions were checked for both the presence of FVIII and anti-FVIII antibodies by the chromogenic assay or a latex agglutination assay, respectively, as described below.
Assay systems for human anti-FVIII antibodies The mixture was incubated for 210 min at 21°C with vigorous shaking. The suspension was then centrifuged and washed successively with GBS-BSA, GBS containing 0.02% Tween, and GBS-BSA. The final pellet was resuspended in 1 ml of GBS-BSA. 50 pg of biotin-labeled rFVIII was added to 500 1 of the avidin-Lx suspension, and the mixture was incubated for 60 min at RT with constant shaking. FVIII-coated Lx (Lx-FVIII) was washed twice with GBS-BSA, and the final pellet was resuspended in 500 ,l GBS-BSA. For the detection of anti-FVIII antibodies, 20 1l of a 1:10 dilution in GBS-BSA of Lx-FVHI was mixed with 20 p1 of the sample in GBS-BSA; the mixture was then incubated for 45 min at 37°C with constant shaking. Agglutination was then measured by automated particle counting of residual nonagglutinated particles. The concentration of anti-FVIII antibodies in the sample was inversely proportional to the number of free particles.
ELISA. FVIII (Hemofil M) was insolubilized on a polystyrene microtitration plate through F(ab')2 fragments of rabbit IgG specific for human vWf, and the binding of anti-FVIII antibodies was detected by addition of peroxidase-labeled goat IgG specific for human Fcy as described (9) . Control Control experiments included addition of biotin-labeled FVII in buffer or mixed with a pool of human gammaglobulins.
Binding to anti-FVIII mAbs. Plates were coated with an anti-FVHI mAb as above. The plates were washed four times in PBS-Tween before addition of 50 Al of FT sample containing 500 Mg IgG/ml in PBS-BSA for an incubation of 2 h at RT. Washing was followed by addition of peroxidase-labeled goat IgG specific for human Fcy (Sigma Chemical Co.), and the binding of human antibodies was detected as described above. Control experiments included plates coated with an mAb of the same isotype but of unrelated specificity and substitution of anti-idiotypic antibodies by a multi-donor pool of gammaglobulins. Biotin-labeled F(ab')2 fragments of FT IgG were also used in this assay. For this, 50 pI of a 250-ag/ml protein solution made in PBS was added to the plate, which was incubated for 2 h at RT. After washing, avidinperoxidase and OPD were added as described above. The binding of F(ab')2 fragments was compared with that of the corresponding biotinlabeled FT antibodies.
Inhibition of the binding of human anti-FVIII antibodies to FVIII. Polystyrene plates (Nunc) were coated overnight with rabbit anti-vWf F(ab')2 fragments and Hemofil-M as described above. 50 Al of human anti-FVHI antibodies diluted to 4 jg/ml in PBS-BSA was mixed with 50 Ml of a sample containing 500 jg/ml of the corresponding FT fraction made in the same buffer. The mixture was incubated for 2 h at RT and added in 50-Al aliquots to FVIH-coated plates for a further 2-h incubation at RT. The plates were washed four times with PBS-Tween before addition of peroxidase-labeled goat IgG specific for human Fcy as described (9) . Control experiments included the addition of the FT fraction alone.
Statistical analysis
Correlations between FVII assays were evaluated by the nonparametric Spearman correlation coefficient test.
Results
Antibody yield and isotype distribution. IgG antibodies recovered by affinity purification and their isotype distribution were quantitated by ELISA. Table I shows that a significant amount of antibodies was obtained from each of the 10 normal serums, with a mean value of 25 ,ug per 10 mg IgG applied to the immunosorbent. It also shows that the isotype distribution of affinity-purified antibodies closely follows the normal distribution of IgG subclasses, with an elevated IgG4 level in only 3 out of the 10 subjects.
Next, the proportion of specific anti-FVIII antibodies in the affinity-purified IgG fraction was calculated using an assay in which antibodies were mixed with a preparation of soluble FVIH-vWf complexes. As shown in Table I , the proportion of anti-FVIII antibodies combined with the FVIII-vWf complex retained on the anti-vWf immunosorbent ranged from 19 to Finally, affinity-purified antibodies were assayed for their capacity to inhibit the function of FVIII in a chromogenic assay. Different concentrations of antibodies were incubated with a predetermined amount of FVIII before addition of the reagents required for the FXa-dependent cleavage of a chromogenic substrate. Fig. 2 shows the dose-response curves for the 10 preparations. It can be seen that in 7 out of the 10 cases a significant inhibition can be obtained. Of interest, a complete inhibition of FVIII activity was observed with four samples used at concentrations of 4.3, 2.1, 2.3, and 1.2 ,ug specific antibodies per milliliter, for subjects 1, 2, 4, and 6, respectively, which corresponded to an antibody to FVIII ratio (wt/wt) of 11, 5, 6 , and 3, respectively. Table II lists the concentrations of antibodies that were required to obtain 20% inhibition of FVIII activity. No significant correlation was found between these concentrations and those needed to obtain a given absorbance in the ELISA system (Spearman correlation coefficient, r, = 0.26, P = NS). Table   II also contains the results of the evaluation of anti-FVIII antibodies carried out on the initial serum samples. In none of the 10 cases was it possible to detect a significant inhibition, either by a conventional inhibition of coagulation assay (< 0.5 Bethesda units/ml) or by using the same chromogenic assay as that used for affinity-purified antibodies (data not shown).
Qualitative evaluation of human anti-factor VIII antibodies. The conclusion that anti-FVIII antibodies are indeed present in the eluates described is strengthened by the following points. Firstly, eluates were adsorbed on protein A. The FT fractions, which contained on average < 2 pg/ml of IgG antibodies, gave negative results in the three assay systems described above, thus excluding the possibility that the anti-FVIII activity in the eluates was nonantibody in nature. Secondly, as the eluates contained a proportion of nonspecific antibodies, we determined whether the anti-FVIII activity could be due to antibodies recovered by adsorption on the matrix or on HSA present in the FVIII preparation used for adsorption. Thus, IgG antibodies prepared from the plasma of 4 out of 10 healthy subjects and of 4 hemophiliac patients, 2 of whom have high levels of FVIII inhibitors, were passed over an HSA immunosorbent prepared by the same procedure as for FVIII.
An average of 53 Isg IgG per 10 mg of total IgG antibodies was recovered in the eluates, for hemophiliac patients as well as for healthy subjects. However, these eluates yielded negative results in all the FVIII assays described above. The anti-FVIII activity in the eluates therefore appears to have been specifically adsorbed by the FVIII on the column.
Thirdly, as rFVIII contained vWf and as anti-vWf antibodies could have interfered in the FVIII assays, the presence of antivWf antibodies in the eluates was evaluated by use of a direct binding ELISA. It showed that the 10 eluates contained < 10 ng/ml (< 0.1%) of anti-vWf antibodies.
Mapping of FVIII epitopes recognized by human anti-FVIII antibodies. Mapping of FVIII epitopes was carried out using a competitive assay in which affinity-purified human antibodies competed with a series of mAbs for the binding to FVIII. The FVII epitope defined by mAb 13 predominates in these data. 8 out of the 10 human antibody preparations inhibited mAb 13 binding to FVII and the mean percentage of competition (45%) was the highest of the panel of mAbs. This suggests that a high proportion of normal subjects make antibodies to (or very close to) the sequence delimited by amino acids 1778 and 1871, which is part of the FVIII A3 domain (Gilles, J. G., K. Peerlinck, J. Arnout, J. Vermylen, and J.-M. R. Saint-Remy, manuscript submitted for publication). This preferential presence of an antibody specific for an epitope located on the light chain prompted us to include in the assay four additional mAbs (ESHI, ESH3, ESH6, and ESH7). All of these four antibodies were partial inhibitors of FVIII activity (9) . Five human antibody preparations were used in the competition assay. A significant inhibition was observed for only one of these preparations (No. 7), with mAbs ESH3 and ESH6 (data not shown). Taken together, the data show a great variation of heavy chain epitope recognition, be they functional or nonfunctional epitopes, while the reactivity towards the light chain was essentially restricted to one out of the six epitopes that could be defined with our mAb panel.
Detection ofhuman anti-idiotypic antibodies. Anti-idiotypic antibodies towards anti-FVHI antibodies were assayed for in the IgG FT fractions. First, care was taken that no residual anti- with biotin-labeled FVIII alone or mixed with one of the IgG FT fractions. Fig. 3 shows the data for the 10 FT fractions and the 8 mAbs. As gammaglobulins from a multi-donor pool did not inhibit the binding of FVIH by > 5% (data not shown), any inhibition above 10% was considered significant. FT fractions were used at either 250 or 500 ,g/ml, in each case with a greater binding at the highest antibody concentration, the latter being illustrated in Fig. 3 . Identical results were obtained when F(ab ' )2 fragments were used instead of whole antibodies. Three mAbs ( 1, 7, and 12) are of particular interest since a significant inhibition of FVHI binding was obtained in 6, 9, and 5 of the 10 cases, respectively. However, we found no obvious correlation between the presence of anti-FVHI antibodies to a given epitope and the presence of corresponding anti-idiotypic antibodies. This particularly applies to mAb 13, which is, as shown above, directed towards a FVIII epitope preferentially recognized by antibodies of healthy subjects. To confirm that the FT antibodies bound to the variable part of mAbs, their capacity to bind directly to the panel of mAbs was measured. This is shown in Fig. 4 ; in each case in which FT antibodies inhibited the binding of labeled rFVI to an mAb, a direct binding to that mAb was observed, while no such binding was observed for unrelated mAbs of the same isotype.
Lastly, the capacity of FT antibodies to inhibit the binding of the corresponding affinity-purified anti-FVIII antibodies to FVIII was measured using 5 of the 10 antibody preparations.
For technical reasons, however, the ratio of anti-FVHI to antiidiotypic antibodies was 10-fold higher in this assay system than the ratio found in the serum. The percentages of inhibition were 26, 15, 7, 38 Monoclonal antibody number
The immunoaffinity method we described has been used previously for the preparation and characterization of anti-FVIII antibodies made by hemophiliac patients (9) . It was shown to effectively deplete specific antibodies from the bulk of nonspecific IgG and to allow for a good recovery of antibodies bound to the immunosorbent. As the immunoadsorption was carried out with a large excess of insolubilized FVIII, we think that the results are probably representative of the situation prevailing in the serum of healthy subjects. That affinity-purified antibodies can be considered as truly specific for FVIII is supported by their capacity to bind soluble FVIII, to recognize FVIH insolubilized by two different methods, and to neutralize the activity of the molecule. In addition, these antibodies specifically inhibited mAb binding to FVIII. This anti-FVIII activity was completely removed by adsorption on protein A, indicating its antibody nature.
The average concentration of anti-FVIII antibodies was 9 For the determination of FVIII epitopes recognized by human affinity-purified antibodies, mAbs specific for either the heavy or the light chains were mixed with specific human antibodies before addition to rFVI-coated polystyrene plates as described in Meth to establish, since the 1778-1871 amino acid region does not contain a site for proteolytic cleavage; it does, however, contain a site for glycosylation, but whether saccharidic moieties can influence FVIH antigenicity is unknown. However, mAbs described by others, and which recognize the same region of the FVIII molecule, have the capacity to inhibit the function of FVIII (15, 16) .
Anti-FVIII activity was not detectable either in the plasma or in a total IgG fraction from the serum. This is probably not an artifact related to the dilution of anti-FVI antibodies in the plasma as compared with affinity-purified antibodies. Thus, Fig.  2 indicates that, at a concentration of 3 gg/ml, all but 1 of the 10 preparations exhibited a significant inhibition of FVHI activity, while the average concentration in serum was 9.4 ug/ ml, taking an average plasma IgG concentration of 10 mg/ml. A likely explanation for this lack of detection in the plasma is that anti-FVIII are neutralized by corresponding anti-idiotypic antibodies. We have shown here that fractions of IgG antibodies that were not retained on the FVIII immunosorbent contained antibodies that inhibited FVIII binding to specific mAbs, recognized the variable part of specific mAbs, and inhibited the binding of specific human antibodies to FVIII. The fact that FT fractions did not contain any detectable FVIII or anti-FVIII antibodies, and that FT antibodies exhibited the same activity either in the form of whole antibody molecules or F(ab' )2 fragments, is evidence for the presence of anti-idiotypic antibodies. The latter are part of the normal immune response in both animals and humans ( 17, 18) , and the antibody response toward FVIII seems to be no exception to this rule. Indeed, multi-donor pools of gammaglobulins contain a significant proportion of anti-idiotypic antibodies ( 19) and the beneficial effect of infusions of pooled gammaglobulins in patients with auto-anti-FVIII antibodies has been demonstrated (20, 21). As it has been shown recently that the main anti-idiotypic activity to anti-FVIII antibodies was carried by IgM antibodies (22), we also searched for such an activity in the IgM fractions obtained from the present healthy subjects, but we failed to find any (data not shown). If the anti-idiotypic activity resided in the IgM fractions, its removal should have revealed the presence of anti-FVIII antibodies in the IgG fraction before adsorption; this was not the case.
However, these anti-idiotypic antibodies did not match exactly the specificity of anti-FVIII antibodies, in particular for antibodies directed towards functional sites of the FVIII molecule. We think this may be due to technical differences between the assay used for epitope mapping and that for detection of antiidiotypic antibodies. It is indeed unlikely that mAbs recognize precisely the same FVIII epitopes as do human antibodies, with the possible exception of mAb 13. In a competition assay where the binding of mAb to insolubilized FVIII is inhibited by human antibodies, inhibition is influenced by steric hindrance. Human antibodies to epitopes located in the proximity of those recognized by mAbs can at least partly prevent mAb binding. An alternative explanation for the lack of close correlation between anti-idiotypic antibodies and anti-FVIII antibodies could be found in the relatively weaker affinity of specific antibodies for anti-idiotypic antibodies bearing a so-called internal image of the antigen than for the antigen itself. Experiments carried out by using human anti-FVIII antibodies and corresponding antiidiotypic antibodies were unfortunately limited by the respective concentration of these two antibody preparations. It was indeed not feasible to use the solution containing anti-idiotypic antibodies at the same concentration (10 mg/ml) as that in the serum, which explains why a complete inhibition of the binding to FVIII was not achieved.
The presence in the serum of normal individuals of antibodies directed toward normal serum proteins has already been demonstrated (23, 24) . The significance of these findings is unknown but it has been suggested that autoantibodies may have a regulatory role (25) . With regard to FVIII, the presence of natural anti-FVIII antibodies has been demonstrated in about 17% of normal subjects, using whole serum in the detection system instead of the purified material prepared here (26) . We observed recently that patients with inhibitors who had been successfully treated by infusions of high doses of FVIII in an attempt to eliminate this undesirable immune response developed high titers of anti-idiotypic antibodies to anti-FVIII inhibitors without significant reduction in the level of antibodies to FVIII (our unpublished data). One might extrapolate from these findings that a method by which anti-idiotypic antibodies towards anti-FVIII antibodies are boosted could be of help in the treatment of patients with inhibitors and represent an alternative to other methods of tolerance induction.
